{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "161bf749",
   "metadata": {},
   "outputs": [],
   "source": [
    "import sys\n",
    "import os\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "os.chdir(root_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "34c8ace2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'/home/helenajun/rag-llm-cancer-paper'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.getcwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "54d06a22",
   "metadata": {},
   "outputs": [],
   "source": [
    "from utils.io import save_object, load_object\n",
    "import pandas as pd\n",
    "from sklearn.model_selection import train_test_split\n",
    "import json\n",
    "_VERSION=\"v1\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "3fcffb2d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "6f97e0e6-46da-4075-bb4b-454946587762",
       "rows": [
        [
         "0",
         "what is the first-line treatment of metastatic urothelial carcinoma with fgfr3 s249c mutation?",
         "GU",
         "['urothelial carcinoma', 'metastatic']",
         "['fgfr3']"
        ],
        [
         "1",
         "are parp inhibitors used for patients with leiomyosarcoma who have mutations in dna damage repair genes?",
         "Sarcoma",
         "['leiomyosarcoma']",
         "['dna', 'parp']"
        ],
        [
         "2",
         "are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?",
         "Sarcoma",
         "['rhabdomyosarcoma']",
         "['alk', 'tfcp2']"
        ],
        [
         "3",
         "for a patient with cancer metastatic prostate cancer, advanced stage (most often stage iv, but some stage iii or earlier potentially) and with brca2 mutation, what drugs approved?",
         "GU",
         "['prostate cancer', 'cancer']",
         "['brca2']"
        ],
        [
         "4",
         "for a patient with her2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "Breast",
         "['breast cancer', 'disease']",
         "['her2']"
        ]
       ],
       "shape": {
        "columns": 4,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>prompt</th>\n",
       "      <th>cancer_category</th>\n",
       "      <th>cancer_type</th>\n",
       "      <th>biomarker</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>what is the first-line treatment of metastatic...</td>\n",
       "      <td>GU</td>\n",
       "      <td>['urothelial carcinoma', 'metastatic']</td>\n",
       "      <td>['fgfr3']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>are parp inhibitors used for patients with lei...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>['leiomyosarcoma']</td>\n",
       "      <td>['dna', 'parp']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>are alk inhibitors approved for use in tfcp2 f...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>['rhabdomyosarcoma']</td>\n",
       "      <td>['alk', 'tfcp2']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>for a patient with cancer metastatic prostate ...</td>\n",
       "      <td>GU</td>\n",
       "      <td>['prostate cancer', 'cancer']</td>\n",
       "      <td>['brca2']</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>for a patient with her2+ breast cancer after n...</td>\n",
       "      <td>Breast</td>\n",
       "      <td>['breast cancer', 'disease']</td>\n",
       "      <td>['her2']</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              prompt cancer_category  \\\n",
       "0  what is the first-line treatment of metastatic...              GU   \n",
       "1  are parp inhibitors used for patients with lei...         Sarcoma   \n",
       "2  are alk inhibitors approved for use in tfcp2 f...         Sarcoma   \n",
       "3  for a patient with cancer metastatic prostate ...              GU   \n",
       "4  for a patient with her2+ breast cancer after n...          Breast   \n",
       "\n",
       "                              cancer_type         biomarker  \n",
       "0  ['urothelial carcinoma', 'metastatic']         ['fgfr3']  \n",
       "1                      ['leiomyosarcoma']   ['dna', 'parp']  \n",
       "2                    ['rhabdomyosarcoma']  ['alk', 'tfcp2']  \n",
       "3           ['prostate cancer', 'cancer']         ['brca2']  \n",
       "4            ['breast cancer', 'disease']          ['her2']  "
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_db_entity_mapped=pd.read_csv(f\"data/real_world_db/real_world_db_entity_mapped_cancerAnnot__{_VERSION}.csv\", index_col=0)\n",
    "real_world_db_entity_mapped.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "03a6ebe7",
   "metadata": {},
   "outputs": [],
   "source": [
    "val, test = train_test_split(\n",
    "    real_world_db_entity_mapped,\n",
    "    test_size=0.88,\n",
    "    stratify=real_world_db_entity_mapped['cancer_category'],\n",
    "    random_state=42\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "2ff1b5ce",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(12, 4)"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "val.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "68648c49",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "dataset",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "count",
         "rawType": "int64",
         "type": "integer"
        }
       ],
       "ref": "935f8787-eabb-4158-af8c-632802777072",
       "rows": [
        [
         "test",
         "90"
        ],
        [
         "validation",
         "12"
        ]
       ],
       "shape": {
        "columns": 1,
        "rows": 2
       }
      },
      "text/plain": [
       "dataset\n",
       "test          90\n",
       "validation    12\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_db_entity_mapped['dataset'] = None\n",
    "real_world_db_entity_mapped.loc[val.index, 'dataset'] = 'validation'\n",
    "real_world_db_entity_mapped.loc[test.index, 'dataset'] = 'test'\n",
    "real_world_db_entity_mapped.dataset.value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "3b887254",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Validation\n",
      "cancer_category\n",
      "GI             0.250000\n",
      "GU             0.250000\n",
      "CNS            0.083333\n",
      "Hematologic    0.083333\n",
      "Endocrine      0.083333\n",
      "Sarcoma        0.083333\n",
      "Lung           0.083333\n",
      "Breast         0.083333\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "Test\n",
      "cancer_category\n",
      "GU             0.211111\n",
      "GI             0.200000\n",
      "Hematologic    0.122222\n",
      "Breast         0.100000\n",
      "CNS            0.088889\n",
      "Sarcoma        0.066667\n",
      "Lung           0.066667\n",
      "Endocrine      0.044444\n",
      "Unspecified    0.033333\n",
      "Other          0.022222\n",
      "Skin           0.022222\n",
      "GYN            0.022222\n",
      "Name: proportion, dtype: float64\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for split_name, split_df in zip(['Validation','Test'], [val,test]):\n",
    "    print(split_name)\n",
    "    print(split_df['cancer_category'].value_counts(normalize=True))\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "19e1bcea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 400x400 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "categories=real_world_db_entity_mapped['cancer_category'].unique()\n",
    "palette = sns.color_palette(\"tab20\", n_colors=len(categories))  # qualitative, up to 20 colors\n",
    "\n",
    "counts = pd.DataFrame({\n",
    "    'Validation': val['cancer_category'].value_counts(),\n",
    "    'Test': test['cancer_category'].value_counts()\n",
    "}).fillna(0)\n",
    "\n",
    "counts.T.plot(kind='bar', stacked=True, color=palette, figsize=(4,4), width=0.3)\n",
    "plt.ylabel(\"Number of queries\")\n",
    "plt.title(\"Cancer type distribution across splits\")\n",
    "plt.legend(loc='center left', bbox_to_anchor=(1, 0.5))\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "934ccf2a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "prompt",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_category",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "cancer_type",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "biomarker",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "dataset",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "e70200dd-c21c-4ef4-901b-d2016e95e00c",
       "rows": [
        [
         "0",
         "what is the first-line treatment of metastatic urothelial carcinoma with fgfr3 s249c mutation?",
         "GU",
         "['urothelial carcinoma', 'metastatic']",
         "['fgfr3']",
         "test"
        ],
        [
         "1",
         "are parp inhibitors used for patients with leiomyosarcoma who have mutations in dna damage repair genes?",
         "Sarcoma",
         "['leiomyosarcoma']",
         "['dna', 'parp']",
         "test"
        ],
        [
         "2",
         "are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?",
         "Sarcoma",
         "['rhabdomyosarcoma']",
         "['alk', 'tfcp2']",
         "validation"
        ],
        [
         "3",
         "for a patient with cancer metastatic prostate cancer, advanced stage (most often stage iv, but some stage iii or earlier potentially) and with brca2 mutation, what drugs approved?",
         "GU",
         "['prostate cancer', 'cancer']",
         "['brca2']",
         "test"
        ],
        [
         "4",
         "for a patient with her2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "Breast",
         "['breast cancer', 'disease']",
         "['her2']",
         "test"
        ]
       ],
       "shape": {
        "columns": 5,
        "rows": 5
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>prompt</th>\n",
       "      <th>cancer_category</th>\n",
       "      <th>cancer_type</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>dataset</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>what is the first-line treatment of metastatic...</td>\n",
       "      <td>GU</td>\n",
       "      <td>['urothelial carcinoma', 'metastatic']</td>\n",
       "      <td>['fgfr3']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>are parp inhibitors used for patients with lei...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>['leiomyosarcoma']</td>\n",
       "      <td>['dna', 'parp']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>are alk inhibitors approved for use in tfcp2 f...</td>\n",
       "      <td>Sarcoma</td>\n",
       "      <td>['rhabdomyosarcoma']</td>\n",
       "      <td>['alk', 'tfcp2']</td>\n",
       "      <td>validation</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>for a patient with cancer metastatic prostate ...</td>\n",
       "      <td>GU</td>\n",
       "      <td>['prostate cancer', 'cancer']</td>\n",
       "      <td>['brca2']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>for a patient with her2+ breast cancer after n...</td>\n",
       "      <td>Breast</td>\n",
       "      <td>['breast cancer', 'disease']</td>\n",
       "      <td>['her2']</td>\n",
       "      <td>test</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                              prompt cancer_category  \\\n",
       "0  what is the first-line treatment of metastatic...              GU   \n",
       "1  are parp inhibitors used for patients with lei...         Sarcoma   \n",
       "2  are alk inhibitors approved for use in tfcp2 f...         Sarcoma   \n",
       "3  for a patient with cancer metastatic prostate ...              GU   \n",
       "4  for a patient with her2+ breast cancer after n...          Breast   \n",
       "\n",
       "                              cancer_type         biomarker     dataset  \n",
       "0  ['urothelial carcinoma', 'metastatic']         ['fgfr3']        test  \n",
       "1                      ['leiomyosarcoma']   ['dna', 'parp']        test  \n",
       "2                    ['rhabdomyosarcoma']  ['alk', 'tfcp2']  validation  \n",
       "3           ['prostate cancer', 'cancer']         ['brca2']        test  \n",
       "4            ['breast cancer', 'disease']          ['her2']        test  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_db_entity_mapped.to_csv(f\"data/real_world_db/real_world_db_split__{_VERSION}.csv\")\n",
    "real_world_db_entity_mapped.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "49b6da04",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(f\"data/real_world_db/real_world_validation_query__{_VERSION}.json\", \"w\") as f:\n",
    "    json.dump(val['prompt'].tolist(), f)\n",
    "\n",
    "with open(f\"data/real_world_db/real_world_test_query__{_VERSION}.json\", \"w\") as f:\n",
    "    json.dump(test['prompt'].tolist(), f)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "25270602",
   "metadata": {},
   "source": [
    "Create ground-truth answers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "b8380264",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Questions",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Expert_curated_ground-truth answers",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "Authors",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "All_onlabel_groundtruth_therapies_cleaned__v1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "GenomicBiomarker_linked_onlabel_groundtruth_therapies__v1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Offlabel_groundtruth_therapies__v1",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Note",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Multiple_biomarkers",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Asking_therapy",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "Asking_genomic_biomarker_linked_therapy",
         "rawType": "object",
         "type": "unknown"
        }
       ],
       "ref": "f81fa237-4516-4a47-bbb6-c1fe88e13ba7",
       "rows": [
        [
         "0",
         "What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ",
         "erdafitinib",
         "Brendan",
         "erdafitinib",
         "erdafitinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "1",
         "Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?",
         "PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "2",
         "Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?",
         "No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "3",
         "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",
         "The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: abiraterone acetate, niraparib, and prednisolone; abiraterone acetate, olaparib, and prednisolone; enzalutamide and talazoparib; olaparib; and rucaparib.",
         "Brendan",
         "niraparib + prednisolone + abiraterone acetate, olaparib + prednisolone + abiraterone acetate, talazoparib + enzalutamide, olaparib, rucaparib",
         "niraparib + prednisolone + abiraterone acetate, olaparib + prednisolone + abiraterone acetate, talazoparib + enzalutamide, olaparib, rucaparib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "4",
         "For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",
         "TDM-1 (ado-trastuzumab emtansine (Kadcyla))",
         "Brendan",
         "trastuzumab emtansine",
         "trastuzumab emtansine",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "5",
         "For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",
         "Yes, the TRK inhibitors Entrectinib, Larotrectinib, and Repotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion.",
         "Brendan",
         "entrectinib, larotrectinib, repotrectinib",
         "entrectinib, larotrectinib, repotrectinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "6",
         "For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",
         "Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",
         "Brendan",
         "pembrolizumab",
         "pembrolizumab",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "7",
         "What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation",
         "While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib, and Repotrectinib.",
         "Brendan",
         "entrectinib, larotrectinib, repotrectinib",
         "entrectinib, larotrectinib, repotrectinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "8",
         "What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?",
         "There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "9",
         "A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",
         "The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "10",
         "A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "11",
         "I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "12",
         "My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "13",
         "For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "14",
         "Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "15",
         "For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "16",
         "For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",
         "The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",
         "Brendan",
         null,
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "17",
         "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",
         "Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.",
         "Brendan",
         "talazoparib, capivasertib + fulvestrant, olaparib",
         "talazoparib, capivasertib + fulvestrant, olaparib",
         null,
         null,
         "True",
         "True",
         "True"
        ],
        [
         "18",
         "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?",
         "The US FDA has approved several therapies for the adjuvant treatment of patients with HER2-positive breast cancer, including: neratinib; pertuzumab; phesgo (pertuzumab and trsatuzumab); trastuzumab deruxtecan; and trastuzumab emtansine. ",
         "Brendan",
         "neratinib, pertuzumab, pertuzumab + trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine",
         "neratinib, pertuzumab, pertuzumab + trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "19",
         "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",
         "Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.",
         "Brendan",
         "sacituzumab govitecan, trastuzumab deruxtecan",
         "sacituzumab govitecan, trastuzumab deruxtecan",
         null,
         null,
         "True",
         "True",
         "True"
        ],
        [
         "20",
         "If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",
         "The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",
         "Brendan",
         "erdafitinib",
         "erdafitinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "21",
         "What drug combination is approved for adults with KRAS G12C-mutated advanced colorectal cancer who have progressed on chemotherapy?",
         "cetuximab and adagrasib",
         "David Yang",
         "cetuximab + adagrasib",
         "cetuximab + adagrasib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "22",
         "What therapy is recommended for patients with recurrent or advanced intrahepatic cholangiocarcinoma and FGFR2 fusion?",
         "futibatinib",
         "David Yang",
         "futibatinib",
         "futibatinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "23",
         "What drug is approved for for patients with grade 2 astrocytoma or oligodendroglioma with IDH1 R132H mutation after surgical resection?",
         "vorasidenib",
         "David Yang",
         "vorasidenib",
         "vorasidenib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "24",
         "I have a patient with stage III NSCLC with an L858R mutation who was treated with chemoradiation and had a partial radiographic response. What are adjuvant therapy options? If there are multiple, what is the preferred option?",
         "osimertinib is the preferred option",
         "David Yang",
         "osimertinib",
         "osimertinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "25",
         "I have a patient with CDK12 mutated metastatic castrate-resistant prostate cancer which has progressed on ADT, abiraterone, and radium. Are there any biomarker-directed therapies that he would be eligible for?",
         "yes, olaparib or enzalutamide with talazoparib",
         "David Yang",
         "olaparib, enzalutamide + talazoparib",
         "olaparib, enzalutamide + talazoparib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "26",
         "I have a patient with newly diagnosed resectable stage IIB non-small cell lung adenocarcinoma with an EGFR exon 19 deletion. What are the approved targeted therapies for this patient in the adjuvant setting?",
         "Following surgical resection of the tumor, an FDA approved adjuvant treatment option is Osimertinib with or without chemotherapy. Peri-operative immunotherapy is generally not recommended in patients with EGFR mutations.  ",
         "Erik Bao",
         "osimertinib, osimertinib + chemotherapy ",
         "osimertinib, osimertinib + chemotherapy ",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "27",
         "I have a patient who is newly diagnosed with metastatic cholangiocarcinoma. Next-generation sequencing of the tumor shows a pathogenic FGFR2 rearrangement. Is there a targeted therapy for this patient? ",
         "The US FDA has not yet approved any biomarker-based treatments for use in the first-line setting for metastatic cholangiocarcinoma. In the second-line or later setting, pemigatinib and futibatinib are FDA approved for treatment of metastatic cholangiocarcinoma with an FGFR2 rearrangement. ",
         "Erik Bao",
         "pemigatinib, futibatinib",
         "pemigatinib, futibatinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "28",
         "I have a patient with metastatic hormone receptor-positive, HER2-low (IHC 1+) breast cancer who progressed on 1st-line treatment with letrozole and ribociclib. Circulating tumor DNA analysis reveals a pathogenic deletion in PTEN. What are approved treatment options in the second-line setting?",
         "FDA-approved targeted therapy options for this patient include fulvestrant + capivasertib (CAPItello-291) and trastuzumab deruxtecan (DESTINY-Breast06). Conventional chemotherapy options include taxanes (e.g., docetaxel, paclitaxel) and capecitabine. ",
         "Erik Bao",
         "fulvestrant + capivasertib, trastuzumab deruxtecan",
         "fulvestrant + capivasertib, trastuzumab deruxtecan",
         "docetaxel, paclitaxel, capecitabine",
         null,
         "True",
         "True",
         "True"
        ],
        [
         "29",
         "I have a patient with newly diagnosed metastatic non-small cell lung cancer. Tumor sequencing identifies a KRAS G12C mutation. What are the approved targeted treatment options for this patient? ",
         "The US FDA has not yet approved any biomarker-based treatments for use in the first-line setting for metastatic non-small cell lung cancer with KRAS G12C mutation. Recommended first-line treatment includes immunotherapy with or without chemotherapy. Adagrasib and sotorasib are targeted treatments that are approved in the second-line setting for metastatic lung cancer with KRAS G12C mutations. ",
         "Erik Bao",
         "adagrasib, sotorasib",
         "adagrasib, sotorasib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "30",
         "I have a patient who is newly diagnosed with metastatic melanoma and has a BRAF V600E mutation. What are the recommended first-line treatment options?",
         "Generally, immunotherapy is the preferred first-line treatment in this setting, with options including nivolumab plus ipilimumab, nivolumab plus relatlimab, and pembrolizumab monotherapy. However, depending on patient context, it is also reasonable and sometimes preferred to opt for FDA-approved targeted therapy options in this setting, which include encorafenib and binimetinib, dabrafenib and trametinib, and vemurafenib and cobimetinib. ",
         "Erik Bao",
         "encorafenib + binimetinib, dabrafenib + trametinib, vemurafenib + cobimetinib",
         "encorafenib + binimetinib, dabrafenib + trametinib, vemurafenib + cobimetinib",
         "nivolumab + ipilimumab, nivolumab + relatlimab, pembrolizumab",
         null,
         "False",
         "True",
         "True"
        ],
        [
         "31",
         "56 year-old patient newly diagnosed with metastatic colorectal cancer with synchronous unresectable liver mets. Genetic testing shows MSI-H status. What are the recommended options for systemic therapy?",
         "PD-1 +/- CTLA-4 specifically pembrolizumab or nivolumab + ipilimumab (recently approved)",
         "Eddy Saad",
         "pembrolizumab, nivolumab + ipilimumab",
         "pembrolizumab, nivolumab + ipilimumab",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "32",
         "66 yo patient with previously resected clear-cell renal cell carcinoma, presents now with local unresectable recurrence. Genetic testing is notable for VHL and PBRM1 mutations, as well as MSI-H. What oprions are recommended for systemic treatment?",
         "Options include: ICI + ICI (nivolumab + ipilimumab) or ICI + VEGF TKI (nivolumab + cabozantinib, pembrolizumab + lenvatinib, pembrolizumab + axitinib, (less commonly even though FDA approved avelumab + axitinib)). Somatic alterations are not predictive of response to treatment in ccRCC. There is insufficient evidence to suggest MSI-H (which is rare in ccRCC) confers additional benefit to nivo + ipi vs ICI + VEGF combinations",
         "Eddy Saad",
         "nivolumab + ipilimumab, nivolumab + cabozantinib, pembrolizumab + lenvatinib,  pembrolizumab + axitinib, avelumab + axitinib",
         null,
         null,
         "Somatic alterations are not predictive of response to treatment in ccRCC. There is insufficient evidence to suggest MSI-H (which is rare in ccRCC) confers additional benefit to nivo + ipi vs ICI + VEGF combinations",
         "True",
         "True",
         "True"
        ],
        [
         "33",
         "70 yo patient with metastatic urothelial carcinoma, having progressed on enfortumab vedotin + pembrolizumab, then gemcitabine + cisplatine. Repeat molecular testing reveals FGFR3 G370C mutations and HER2 IHC 3+ status. What would you recommend for 3rd line therapy?",
         "Erdafitinib (highest level of evidence given FGFR3 alteration). Trastuzumab deruxtecan is another reasonable option (tumor-agnostic approval)",
         "Eddy Saad",
         "erdafitinib, trastuzumab deruxtecan",
         "erdafitinib, trastuzumab deruxtecan",
         null,
         null,
         "True",
         "True",
         "True"
        ],
        [
         "34",
         "73 yo patient with a new diagnosis of metastatic urothelial carcinoma. Molecular testing reveals FGFR3 G370C mutations and HER2 IHC 3+ status. What options would you recommend for systemic treatment?",
         "Enfortumab vedotin (erdafitinib is not approved in the 1st line setting)",
         "Eddy Saad",
         "enfortumab vedotin",
         null,
         null,
         "erdafitinib is not approved in the 1st line setting",
         "True",
         "True",
         "True"
        ],
        [
         "35",
         "67 yo patient presenting with a 7 cm renal mass which was surgically resected 2 months ago. Pathology reveals a clear-cell renal cell carcinoma tumor, grade 2, confined to the kidney. Genetic testing was done and was positive for VHL, BAP1 and PTEN mutations. Repeat scan is NED. What systemic treatment should this patient receive?",
         "None (patient does not meet criteria for adjuvant pembrolizumab)",
         "Eddy Saad",
         null,
         null,
         null,
         "not meeting criteria for adjuvant pembrolizumab",
         "True",
         "True",
         "True"
        ],
        [
         "36",
         "I have a patient with metastatic bladder cancer who has progressed on chemotherapy. Genomics testing revealed a focal amplification of the JAK2/PD-L1 locus. What are the treatment options?",
         "I believe the US FDA has not approved pan-cancer indications for ICI given this genomic event, but there is suggestive data on this being useful in this setting. Standard of care options include EV + pembrolizumab",
         "Eli",
         null,
         null,
         "EV + pembrolizumab (standard of care)",
         null,
         "False",
         "True",
         "True"
        ],
        [
         "37",
         "My metastatic cutaneous melanoma patient has high TMB and a BRAF mutation. What should I do?",
         "First line treatment should be ICI combination (ipilimumab/nivolumab) first, and RAF/MEK inhibitor is second line",
         "Eli",
         "ipilimumab + nivolumab, vemurafenib + cobimetinib + atezolizumab, binimetinib + encorafenib, vemurafenib + cobimetinib, dabrafenib, trametinib + dabrafenib, trametinib, vemurafenib",
         "vemurafenib + cobimetinib + atezolizumab, binimetinib + encorafenib, vemurafenib + cobimetinib, dabrafenib, trametinib + dabrafenib, trametinib, vemurafenib",
         null,
         null,
         "True",
         "True",
         "True"
        ],
        [
         "38",
         "My patient has newly diagnosed acute myeloid leukemia and a FLT3 mutation. Are there targeted therapy options that I should consider in this setting?",
         "Quizartinib in combination with chemotherapy; Midostaurin in combination with chemotherapy; Gilertinib is in relapsed/refractory FLT3-mutant AML",
         "Eli",
         "quizartinib + anthracycline + cytarabine, midostaurin + daunorubicin + cytarabine, gilertinib",
         "quizartinib + anthracycline + cytarabine, midostaurin + daunorubicin + cytarabine, gilertinib",
         null,
         "quizartinib is not listed the moalmanac db",
         "False",
         "True",
         "True"
        ],
        [
         "39",
         "I have a patient with radioactive iodine referactory thyroid cancer. what is the first line option?",
         "lenvatinib",
         "Theodora",
         "lenvatinib",
         null,
         null,
         null,
         "False",
         "True",
         "False"
        ],
        [
         "40",
         "my patient with newly diagnosed anaplastic thyroid cancer istage IVC s found to have a BRAFV600E positive tumor.  what is the best next step for systemic therapy?",
         "dabrafenib/trametinib",
         "Theodora",
         "dabrafenib + trametinib",
         "dabrafenib + trametinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "41",
         "if a patient with radioactive iodine refractory thyroid cancer progresses on lenvatinib and the tumor has a RAS mutation, what do I do? ",
         "switch to cabozantinib (or sorafenib, rarely used but in NCCN guidelines)",
         "Theodora",
         "cabozantinib",
         null,
         "sorafenib (in NCCN guideline)",
         null,
         "False",
         "True",
         "True"
        ],
        [
         "42",
         "if a patient with radioactive iodine refractory thyroid cancer progresses on lenvatinib and the tumor has a BRAFV600E mutation, what do I do?",
         "dabrafenib/trametinib vs cabozantinib",
         "Theodora",
         "dabrafenib + trametinib, cabozantinib",
         "dabrafenib + trametinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "43",
         "if a patient with progressive or metastatic medullary thyroid cancer needs systemic therapy and the tumor has a RET mutation, what is preferred first line treatment?",
         "selpercatinib",
         "Theodora",
         "selpercatinib",
         "selpercatinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "44",
         "In a patient with follicular lymphoma with an activating EZH2 mutation, what treatment is indicated?",
         "tazemetostat",
         null,
         "tazemetostat",
         "tazemetostat",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "45",
         "For a patient with osteosarcoma and MYC amplification, what treatment is indicated?",
         "Methotrexate, doxorubicin, cisplatin",
         "Riaz",
         "methotrexate, doxorubicin, cisplatin",
         null,
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "46",
         "For a patient with relapsed B-ALL that expresses CD22, what antibody-drug conjugates may be used?",
         "Inotuzomab ozogamicin",
         "Riaz",
         "inotuzomab ozogamicin",
         "inotuzomab ozogamicin",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "47",
         "For a patient with relapsed B-ALL that expresses CD19, what targeted treatment options exist?",
         "CAR-T cell therapy, Blinatumomab",
         "Riaz",
         "CAR-T cell therapy, blinatumomab",
         "blinatumomab",
         null,
         "CAR-T cell therapies are not included in moalmanac db",
         "False",
         "True",
         "True"
        ],
        [
         "48",
         "What targeted treatment options exist for patients with AML and FLT3-ITD?",
         "Gilteritinib",
         "Riaz",
         "gilteritinib",
         "gilteritinib",
         null,
         null,
         "False",
         "True",
         "True"
        ],
        [
         "49",
         "What targeted treatment option is available for patients with high-risk neuroblastoma and an activating ALK mutation?",
         "Lorlatinib",
         "Riaz",
         null,
         null,
         "lorlatinib",
         null,
         "False",
         "True",
         "True"
        ]
       ],
       "shape": {
        "columns": 10,
        "rows": 102
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Questions</th>\n",
       "      <th>Expert_curated_ground-truth answers</th>\n",
       "      <th>Authors</th>\n",
       "      <th>All_onlabel_groundtruth_therapies_cleaned__v1</th>\n",
       "      <th>GenomicBiomarker_linked_onlabel_groundtruth_therapies__v1</th>\n",
       "      <th>Offlabel_groundtruth_therapies__v1</th>\n",
       "      <th>Note</th>\n",
       "      <th>Multiple_biomarkers</th>\n",
       "      <th>Asking_therapy</th>\n",
       "      <th>Asking_genomic_biomarker_linked_therapy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>What is the first-line treatment of metastatic...</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>Brendan</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>erdafitinib</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Are PARP inhibitors used for patients with lei...</td>\n",
       "      <td>PARP inhibitors are not yet approved for the t...</td>\n",
       "      <td>Brendan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Are ALK inhibitors approved for use in TFCP2 f...</td>\n",
       "      <td>No, no ALK inhibitors are currently approved f...</td>\n",
       "      <td>Brendan</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>For a patient with cancer metastatic prostate ...</td>\n",
       "      <td>The following therapy and combination therapie...</td>\n",
       "      <td>Brendan</td>\n",
       "      <td>niraparib + prednisolone + abiraterone acetate...</td>\n",
       "      <td>niraparib + prednisolone + abiraterone acetate...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>For a patient with HER2+ breast cancer after n...</td>\n",
       "      <td>TDM-1 (ado-trastuzumab emtansine (Kadcyla))</td>\n",
       "      <td>Brendan</td>\n",
       "      <td>trastuzumab emtansine</td>\n",
       "      <td>trastuzumab emtansine</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>What is an acceptable treatment in patients wi...</td>\n",
       "      <td>Elacestrant</td>\n",
       "      <td>Chris Labaki</td>\n",
       "      <td>elacestrant</td>\n",
       "      <td>elacestrant</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>What is an acceptable regimen in patients with...</td>\n",
       "      <td>Pembrolizumab with trastuzumab, fluoropyrimidi...</td>\n",
       "      <td>Chris Labaki</td>\n",
       "      <td>trastuzumab + fluorouracil + cisplatin + pembr...</td>\n",
       "      <td>trastuzumab + fluorouracil + cisplatin + pembr...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>Are there any genomically guided therapies tha...</td>\n",
       "      <td>olaparib, enzalutamide + talazoparib, predniso...</td>\n",
       "      <td>Helena</td>\n",
       "      <td>olaparib, enzalutamide + talazoparib, predniso...</td>\n",
       "      <td>olaparib, enzalutamide + talazoparib, predniso...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>Which drugs are currently approved for the tre...</td>\n",
       "      <td>nirogacestat</td>\n",
       "      <td>Helena</td>\n",
       "      <td>nirogacestat</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>What are the current options for the first-lin...</td>\n",
       "      <td>nivolumab + cabozantinib, nivolumab + ipilimum...</td>\n",
       "      <td>Helena</td>\n",
       "      <td>nivolumab + cabozantinib, nivolumab + ipilimum...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>True</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>102 rows × 10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                             Questions  \\\n",
       "0    What is the first-line treatment of metastatic...   \n",
       "1    Are PARP inhibitors used for patients with lei...   \n",
       "2    Are ALK inhibitors approved for use in TFCP2 f...   \n",
       "3    For a patient with cancer metastatic prostate ...   \n",
       "4    For a patient with HER2+ breast cancer after n...   \n",
       "..                                                 ...   \n",
       "97   What is an acceptable treatment in patients wi...   \n",
       "98   What is an acceptable regimen in patients with...   \n",
       "99   Are there any genomically guided therapies tha...   \n",
       "100  Which drugs are currently approved for the tre...   \n",
       "101  What are the current options for the first-lin...   \n",
       "\n",
       "                   Expert_curated_ground-truth answers       Authors  \\\n",
       "0                                          erdafitinib       Brendan   \n",
       "1    PARP inhibitors are not yet approved for the t...       Brendan   \n",
       "2    No, no ALK inhibitors are currently approved f...       Brendan   \n",
       "3    The following therapy and combination therapie...       Brendan   \n",
       "4          TDM-1 (ado-trastuzumab emtansine (Kadcyla))       Brendan   \n",
       "..                                                 ...           ...   \n",
       "97                                         Elacestrant  Chris Labaki   \n",
       "98   Pembrolizumab with trastuzumab, fluoropyrimidi...  Chris Labaki   \n",
       "99   olaparib, enzalutamide + talazoparib, predniso...        Helena   \n",
       "100                                       nirogacestat        Helena   \n",
       "101  nivolumab + cabozantinib, nivolumab + ipilimum...        Helena   \n",
       "\n",
       "         All_onlabel_groundtruth_therapies_cleaned__v1  \\\n",
       "0                                          erdafitinib   \n",
       "1                                                  NaN   \n",
       "2                                                  NaN   \n",
       "3    niraparib + prednisolone + abiraterone acetate...   \n",
       "4                                trastuzumab emtansine   \n",
       "..                                                 ...   \n",
       "97                                         elacestrant   \n",
       "98   trastuzumab + fluorouracil + cisplatin + pembr...   \n",
       "99   olaparib, enzalutamide + talazoparib, predniso...   \n",
       "100                                       nirogacestat   \n",
       "101  nivolumab + cabozantinib, nivolumab + ipilimum...   \n",
       "\n",
       "    GenomicBiomarker_linked_onlabel_groundtruth_therapies__v1  \\\n",
       "0                                          erdafitinib          \n",
       "1                                                  NaN          \n",
       "2                                                  NaN          \n",
       "3    niraparib + prednisolone + abiraterone acetate...          \n",
       "4                                trastuzumab emtansine          \n",
       "..                                                 ...          \n",
       "97                                         elacestrant          \n",
       "98   trastuzumab + fluorouracil + cisplatin + pembr...          \n",
       "99   olaparib, enzalutamide + talazoparib, predniso...          \n",
       "100                                                NaN          \n",
       "101                                                NaN          \n",
       "\n",
       "    Offlabel_groundtruth_therapies__v1 Note Multiple_biomarkers  \\\n",
       "0                                  NaN  NaN               False   \n",
       "1                                  NaN  NaN               False   \n",
       "2                                  NaN  NaN               False   \n",
       "3                                  NaN  NaN               False   \n",
       "4                                  NaN  NaN               False   \n",
       "..                                 ...  ...                 ...   \n",
       "97                                 NaN  NaN                True   \n",
       "98                                 NaN  NaN                True   \n",
       "99                                 NaN  NaN               False   \n",
       "100                                NaN  NaN               False   \n",
       "101                                NaN  NaN               False   \n",
       "\n",
       "    Asking_therapy Asking_genomic_biomarker_linked_therapy  \n",
       "0             True                                    True  \n",
       "1             True                                    True  \n",
       "2             True                                    True  \n",
       "3             True                                    True  \n",
       "4             True                                    True  \n",
       "..             ...                                     ...  \n",
       "97            True                                    True  \n",
       "98            True                                    True  \n",
       "99            True                                    True  \n",
       "100           True                                   False  \n",
       "101           True                                   False  \n",
       "\n",
       "[102 rows x 10 columns]"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_db=pd.read_csv(f\"data/real_world_db/updated_real_world_queries_answers__{_VERSION}.csv\", index_col=0)\n",
    "real_world_db=real_world_db.dropna(subset='Questions').reset_index(drop=True)\n",
    "real_world_db"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "f2c339e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_world_db_entity_mapped['All_onlabel_groundtruth_therapies_cleaned__v2'] = None\n",
    "\n",
    "def parse_therapies(entry):\n",
    "    if isinstance(entry, str):\n",
    "        parts = entry.split(',')\n",
    "        if len(parts) > 1:\n",
    "            return [set(d.strip().split(' + ')) for d in parts]\n",
    "        else:\n",
    "            return [set(parts)]\n",
    "    else:\n",
    "        return []\n",
    "    \n",
    "real_world_db_entity_mapped['All_onlabel_groundtruth_therapies_cleaned__v2']=real_world_db['All_onlabel_groundtruth_therapies_cleaned__v1'].apply(parse_therapies)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "24b511f8",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_world_db_entity_mapped.to_csv(f\"data/real_world_db/real_world_db__{_VERSION}.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "837733d4",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_world_query_therapy_pair_dict= dict(zip(real_world_db_entity_mapped['prompt'], real_world_db_entity_mapped['All_onlabel_groundtruth_therapies_cleaned__v2']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "d7caa30e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'what is the first-line treatment of metastatic urothelial carcinoma with fgfr3 s249c mutation?': [{'erdafitinib'}],\n",
       " 'are parp inhibitors used for patients with leiomyosarcoma who have mutations in dna damage repair genes?': [],\n",
       " 'are alk inhibitors approved for use in tfcp2 fusion positive rhabdomyosarcoma?': [],\n",
       " 'for a patient with cancer metastatic prostate cancer, advanced stage (most often stage iv, but some stage iii or earlier potentially) and with brca2 mutation, what drugs approved?': [{'abiraterone acetate',\n",
       "   'niraparib',\n",
       "   'prednisolone'},\n",
       "  {'abiraterone acetate', 'olaparib', 'prednisolone'},\n",
       "  {'enzalutamide', 'talazoparib'},\n",
       "  {'olaparib'},\n",
       "  {'rucaparib'}],\n",
       " 'for a patient with her2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?': [{'trastuzumab emtansine'}],\n",
       " 'for patients with advanced cancer and with ntrk fusions, regardless of cancer types, are there drugs approved?': [{'entrectinib'},\n",
       "  {'larotrectinib'},\n",
       "  {'repotrectinib'}],\n",
       " 'for patients with advanced cancer and with high tmb, regardless of cancer types, are there drugs approved?': [{'pembrolizumab'}],\n",
       " 'what fda-approved therapies exist for a stage iv pancreatic ductal adenocarcinoma patient with a ntrk mutation': [{'entrectinib'},\n",
       "  {'larotrectinib'},\n",
       "  {'repotrectinib'}],\n",
       " 'what are available fda-approved targeted therapies in patients with fgfr2 mutated bladder cancer? in which disease setting are they approved (metastatic disease only or peri-operative)?': [],\n",
       " 'a patient with localized ewing sarcoma has a stag2 mutation, and has just relapsed. what are reasonable relapse regimens to consider?': [],\n",
       " 'a patient with relapsed high-risk neuroblastoma has alk mutation x. should they receive an alk inhibitor, and if so, which one?': [],\n",
       " 'i have a 3 year old patient with neuroblastoma in the setting of a germline bard1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?': [],\n",
       " 'my 20 year old patient with alk mutated neuroblastoma has failed therapy with broad chemotherapy, radiation, and an alk inhibitor. what is a good next line and what evidence supports this choice?': [],\n",
       " 'for a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and myc amplification, are there effective salvage therapies? what evidence supports them?': [],\n",
       " 'is there an optimal drug combination to minimize the risk of post hsct relapse in a 2 year old with kmt2a rearranged aml?': [],\n",
       " 'for a 4 year old patient with medulloblastoma, shh subtype, and a germline ptch1 mutation, are there therapies specifically targeting this pathway?': [],\n",
       " 'for toddler with unresectable hepatoblastoma and a ctnnb1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?': [],\n",
       " 'i have a patient with de novo metastatic hr+ breast cancer with both a somatic akt mutation and a germline brca2 mutation - what are the standard, recommended first- and second-line treatments for this patient?': [{'talazoparib'},\n",
       "  {'capivasertib', 'fulvestrant'},\n",
       "  {'olaparib'}],\n",
       " 'i have a patient with an initial diagnosis of ct3n1 her2+ breast cancer who received neoadjuvant tchp and had 1cm of residual disease at surgery. what is the recommended adjuvant treatment for this patient and what are the clinical trials that i should consider?': [{'neratinib'},\n",
       "  {'pertuzumab'},\n",
       "  {'pertuzumab', 'trastuzumab'},\n",
       "  {'trastuzumab deruxtecan'},\n",
       "  {'trastuzumab emtansine'}],\n",
       " 'i have a patient with metastatic hr-negative, her2-low, pd-l1-negative, breast cancer with no germline brca mutation.  for second line, is t-dxd or sacituzumab govitecan preferred?': [{'sacituzumab govitecan'},\n",
       "  {'trastuzumab deruxtecan'}],\n",
       " 'if a bladder cancer patient has fgfr3 mutations, what would be the recommended next lines of treatment?': [{'erdafitinib'}],\n",
       " 'what drug combination is approved for adults with kras g12c-mutated advanced colorectal cancer who have progressed on chemotherapy?': [{'cetuximab + adagrasib'}],\n",
       " 'what therapy is recommended for patients with recurrent or advanced intrahepatic cholangiocarcinoma and fgfr2 fusion?': [{'futibatinib'}],\n",
       " 'what drug is approved for for patients with grade 2 astrocytoma or oligodendroglioma with idh1 r132h mutation after surgical resection?': [{'vorasidenib'}],\n",
       " 'i have a patient with stage iii nsclc with an l858r mutation who was treated with chemoradiation and had a partial radiographic response. what are adjuvant therapy options? if there are multiple, what is the preferred option?': [{'osimertinib'}],\n",
       " 'i have a patient with cdk12 mutated metastatic castrate-resistant prostate cancer which has progressed on adt, abiraterone, and radium. are there any biomarker-directed therapies that he would be eligible for?': [{'olaparib'},\n",
       "  {'enzalutamide', 'talazoparib'}],\n",
       " 'i have a patient with newly diagnosed resectable stage iib non-small cell lung adenocarcinoma with an egfr exon 19 deletion. what are the approved targeted therapies for this patient in the adjuvant setting?': [{'osimertinib'},\n",
       "  {'chemotherapy', 'osimertinib'}],\n",
       " 'i have a patient who is newly diagnosed with metastatic cholangiocarcinoma. next-generation sequencing of the tumor shows a pathogenic fgfr2 rearrangement. is there a targeted therapy for this patient?': [{'pemigatinib'},\n",
       "  {'futibatinib'}],\n",
       " 'i have a patient with metastatic hormone receptor-positive, her2-low (ihc 1+) breast cancer who progressed on 1st-line treatment with letrozole and ribociclib. circulating tumor dna analysis reveals a pathogenic deletion in pten. what are approved treatment options in the second-line setting?': [{'capivasertib',\n",
       "   'fulvestrant'},\n",
       "  {'trastuzumab deruxtecan'}],\n",
       " 'i have a patient with newly diagnosed metastatic non-small cell lung cancer. tumor sequencing identifies a kras g12c mutation. what are the approved targeted treatment options for this patient?': [{'adagrasib'},\n",
       "  {'sotorasib'}],\n",
       " 'i have a patient who is newly diagnosed with metastatic melanoma and has a braf v600e mutation. what are the recommended first-line treatment options?': [{'binimetinib',\n",
       "   'encorafenib'},\n",
       "  {'dabrafenib', 'trametinib'},\n",
       "  {'cobimetinib', 'vemurafenib'}],\n",
       " '56 year-old patient newly diagnosed with metastatic colorectal cancer with synchronous unresectable liver mets. genetic testing shows msi-h status. what are the recommended options for systemic therapy?': [{'pembrolizumab'},\n",
       "  {'ipilimumab', 'nivolumab'}],\n",
       " '66 yo patient with previously resected clear-cell renal cell carcinoma, presents now with local unresectable recurrence. genetic testing is notable for vhl and pbrm1 mutations, as well as msi-h. what oprions are recommended for systemic treatment?': [{'ipilimumab',\n",
       "   'nivolumab'},\n",
       "  {'cabozantinib', 'nivolumab'},\n",
       "  {'lenvatinib', 'pembrolizumab'},\n",
       "  {'axitinib', 'pembrolizumab'},\n",
       "  {'avelumab', 'axitinib'}],\n",
       " '70 yo patient with metastatic urothelial carcinoma, having progressed on enfortumab vedotin + pembrolizumab, then gemcitabine + cisplatine. repeat molecular testing reveals fgfr3 g370c mutations and her2 ihc 3+ status. what would you recommend for 3rd line therapy?': [{'erdafitinib'},\n",
       "  {'trastuzumab deruxtecan'}],\n",
       " '73 yo patient with a new diagnosis of metastatic urothelial carcinoma. molecular testing reveals fgfr3 g370c mutations and her2 ihc 3+ status. what options would you recommend for systemic treatment?': [{'enfortumab vedotin'}],\n",
       " '67 yo patient presenting with a 7 cm renal mass which was surgically resected 2 months ago. pathology reveals a clear-cell renal cell carcinoma tumor, grade 2, confined to the kidney. genetic testing was done and was positive for vhl, bap1 and pten mutations. repeat scan is ned. what systemic treatment should this patient receive?': [],\n",
       " 'i have a patient with metastatic bladder cancer who has progressed on chemotherapy. genomics testing revealed a focal amplification of the jak2/pd-l1 locus. what are the treatment options?': [],\n",
       " 'my metastatic cutaneous melanoma patient has high tmb and a braf mutation. what should i do?': [{'ipilimumab',\n",
       "   'nivolumab'},\n",
       "  {'atezolizumab', 'cobimetinib', 'vemurafenib'},\n",
       "  {'binimetinib', 'encorafenib'},\n",
       "  {'cobimetinib', 'vemurafenib'},\n",
       "  {'dabrafenib'},\n",
       "  {'dabrafenib', 'trametinib'},\n",
       "  {'trametinib'},\n",
       "  {'vemurafenib'}],\n",
       " 'my patient has newly diagnosed acute myeloid leukemia and a flt3 mutation. are there targeted therapy options that i should consider in this setting?': [{'anthracycline',\n",
       "   'cytarabine',\n",
       "   'quizartinib'},\n",
       "  {'cytarabine', 'daunorubicin', 'midostaurin'},\n",
       "  {'gilertinib'}],\n",
       " 'i have a patient with radioactive iodine referactory thyroid cancer. what is the first line option?': [{'lenvatinib'}],\n",
       " 'my patient with newly diagnosed anaplastic thyroid cancer istage ivc s found to have a brafv600e positive tumor.  what is the best next step for systemic therapy?': [{'dabrafenib + trametinib'}],\n",
       " 'if a patient with radioactive iodine refractory thyroid cancer progresses on lenvatinib and the tumor has a ras mutation, what do i do?': [{'cabozantinib'}],\n",
       " 'if a patient with radioactive iodine refractory thyroid cancer progresses on lenvatinib and the tumor has a brafv600e mutation, what do i do?': [{'dabrafenib',\n",
       "   'trametinib'},\n",
       "  {'cabozantinib'}],\n",
       " 'if a patient with progressive or metastatic medullary thyroid cancer needs systemic therapy and the tumor has a ret mutation, what is preferred first line treatment?': [{'selpercatinib'}],\n",
       " 'in a patient with follicular lymphoma with an activating ezh2 mutation, what treatment is indicated?': [{'tazemetostat'}],\n",
       " 'for a patient with osteosarcoma and myc amplification, what treatment is indicated?': [{'methotrexate'},\n",
       "  {'doxorubicin'},\n",
       "  {'cisplatin'}],\n",
       " 'for a patient with relapsed b-all that expresses cd22, what antibody-drug conjugates may be used?': [{'inotuzomab ozogamicin'}],\n",
       " 'for a patient with relapsed b-all that expresses cd19, what targeted treatment options exist?': [{'CAR-T cell therapy'},\n",
       "  {'blinatumomab'}],\n",
       " 'what targeted treatment options exist for patients with aml and flt3-itd?': [{'gilteritinib'}],\n",
       " 'what targeted treatment option is available for patients with high-risk neuroblastoma and an activating alk mutation?': [],\n",
       " 'for a patient with lung adenocarcinoma and a kras g12c mutation, what targeted treatments are approved and for what stage?': [{'sotorasib'},\n",
       "  {'adagrasib'}],\n",
       " 'a patient has metastatic non small cell lung cancer with an egfr exon 20 insertion, is there a targeted treatment for them?': [{'amivantamab',\n",
       "   'carboplatin',\n",
       "   'pemetrexed'},\n",
       "  {'mobocertinib'}],\n",
       " 'are there specific therapies for patients with endometrial carcinoma and li fraumeni?': [],\n",
       " 'can we target chek2 mutations for patients with metastatic breast carcinoma?': [],\n",
       " 'is there a first line targeted therapy for patients with lung cancer and a ros1 rearrangement?': [{'crizotinib'},\n",
       "  {'entrectinib'},\n",
       "  {'repotrectinib'},\n",
       "  {'taletrectinib'}],\n",
       " 'what options are available for children with bard1 germline mutated neuroblastoma?': [],\n",
       " 'what can target high grade wilms tumor with wt1 mutation': [],\n",
       " 'are there any targeted thereapies available to prevent transformation of plexiform neurofibroma to malignant peripheral nerve sheath tumor in patients with neurofibromatosis type 1?': [{'selumetanib'}],\n",
       " 'what can i do for a patient with osteosarcoma secondary to li fraumeni syndrome?': [{'talazoparib'}],\n",
       " 'are there any targeted treatments for h3k27m diffuse midline glioma?': [],\n",
       " 'for patients with muscle-invasive bladder cancer, are there systemic treatment options prior to radical cystectomy?': [{'cisplatin + durvalumab'}],\n",
       " 'are there genomic alterations that predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer?': [],\n",
       " 'what is the first line systemic therapy for locally advanced or metastatic bladder cancer?': [{'enfortumab vedotin + pembrolizumab'}],\n",
       " 'i have a patient with newly diagnosed aml that has mutations in tp53 and idh1. are there any therapies that i should be thinking about in this setting?': [{'ivosidenib'}],\n",
       " 'my patient whas relapsed aml that includes an idh2 mutation. what is the correct treatment strategy based on this information?': [{'enasidenib'}],\n",
       " 'i have a patient with metastatic cholangiocarcinoma and an fgfr2 fusion. this patient has already progressed on standard first-line treatments. are there any approved therapies i should consider?': [{'pemigatinib'},\n",
       "  {'futibatinib'}],\n",
       " 'my advanced cholangiocarcinoma patient has progressed, but tumor molecular profiling shows evidence for an activating idh1 mutation. can this be targeted for this patient?': [{'ivosidenib'}],\n",
       " 'for a cll patient with del 17p are there targeted therapies i could consider?': [{'ibrutinib'}],\n",
       " 'for a patient with nut midline carcinoma and known brd4-nut fusion, is there a targeted therapy for their disease?': [],\n",
       " 'for a patient with a bcor::ccnb3 fusion (bcs), is there a targeted therapy?': [],\n",
       " 'a patient has mismatch repair deficient colo-rectal carcinoma. should they receive nivolumab?': [{'nivolumab'}],\n",
       " 'i have a post-menopausal female patient with metastatic er+pr+her2-low (ihc 1+) lobular breast cancer involving the bones, lymph nodes, and leptomeninges who was found to have metastatic disease 9 months after completing adjuvant letrozole plus lupron (ai + ofs). she has not received treatment yet in the metastatic setting. she was found to have a pik3ca mutation on ctdna. what are her first-line treatment options?': [{'fulvestrant',\n",
       "   'inavolisib',\n",
       "   'palbociclib'},\n",
       "  {'abemaciclib', 'fulvestrant'},\n",
       "  {'trastuzumab deruxtecan'}],\n",
       " 'i have a post-menopausal female patient who was diagnosed with stage 2 (pt2n1) er+her2-negative breast cancer with oncotype dx score 32 and a germline brca2 mutation. she received a lumpectomy and adjuvant radiation. what are the next steps in treatment?': [{'olaparib'},\n",
       "  {'fulvestrant', 'ribociclib'},\n",
       "  {'abemaciclib'},\n",
       "  {'abemaciclib', 'letrozole'},\n",
       "  {'abemaciclib', 'anastrozole'},\n",
       "  {'abemaciclib', 'exemestane'}],\n",
       " 'i have a male patient with de novo metastatic gastric adenocarcinoma that was her2 3+ and pd-l1 cps 10 on ihc of a liver biopsy. what is the first line of treatment?': [{'cisplatin',\n",
       "   'fluorouracil',\n",
       "   'pembrolizumab',\n",
       "   'trastuzumab'},\n",
       "  {'capecitabine', 'oxaliplatin', 'pembrolizumab', 'trastuzumab'}],\n",
       " 'i have a post-menopausal female patient with high grade serious ovarian carcinoma with peritoneal carcinomatosis who received surgical debulking/ cytoreduction surgery. she is found to have a germline brca1 mutation. she received first-line platinum chemotherapy. what are the approved drugs for maintenance therapy?': [{'olaparib'},\n",
       "  {'niratinib'},\n",
       "  {'bevacizumab', 'olaparib'}],\n",
       " 'i have a male patient, never smoker, with de novo metastatic lung adenocarcinoma involving the cns. molecular testing reveals an alk rearrangement and pd-l1 tps 15%. what are the first-line treatment options?': [{'alectinib'},\n",
       "  {'brigatinib'},\n",
       "  {'lorlatinib'},\n",
       "  {'crizotinib'}],\n",
       " 'i have a patient with metastatic ascending colon adenocarcinoma, that is kras and braf wt, what first line targeted therapy therapy options are there in addition to folfox or folfiri': [{'bevacizumab'}],\n",
       " 'i have a patient with metastatic descending colon adenocarcinoma, that is kras and braf wt, what first line targeted therapy therapy options are there in addition to folfox or folfiri': [{'cetuximab'},\n",
       "  {'panitumumab'},\n",
       "  {'bevacizumab'}],\n",
       " 'i have a patient with metastatic descending colon adenocarcinoma, that is kras wt and braf mutant, what targeted therapy therapy options are there in the first line setting': [{'centuximab',\n",
       "   'encorafenib'},\n",
       "  {'bevacizumab'}],\n",
       " 'i have a patient with metastatic descending colon adenocarcinoma, that is kras g12d mutant and braf wt, what first line targeted therapy therapy options are there in addition to folfox or folfiri': [{'bevacizumab'}],\n",
       " 'i have a patient with unresectable fgfr fusion cholangiocarcinoma, what targeted treatment options are available in the first line': [],\n",
       " 'i have a patient with unresectable idh1 mutant cholangiocarcinoma, what targeted treatment options are available in the first line': [],\n",
       " 'i have a patient with metastatic castration resistant prostate cancer and a fanca mutation, can i give them a parp inhibitor?': [{'enzalutamide + talazoparib'}],\n",
       " 'my patient with prostate cancer had genomic testing on their tumor and her2 amplification was detected. can i give them trastuzumab deruxtecan or another her2-targeted therapy?': [{'trastuzumab deruxtecan'}],\n",
       " 'i have a patient with advanced kidney cancer and the primary tumor had a mutation in pbrm1. what is the treatment implication of this mutation': [],\n",
       " 'my patient with platinum-refractory metastatic testicular cancer has a tp53 mutation. how should i treat them?': [],\n",
       " 'i have a patient with metastatic prostate cancer and an spop mutation. what is the best therapeutic option?': [],\n",
       " 'my patient with her2+, metastatic or unresectable colorectal cancer has progressed after progression on both folfox and folfiri-based regimens. what treatment options are available?': [{'trastuzumab + tucatinib'}],\n",
       " 'my patient with her2+, metastatic or unresectable biliary tract cancer has progressed on a gemcitabine-based regimen. what treatment options are available?': [{'zanidatamab'}],\n",
       " 'my patient with metastatic or unresectable pancreatic adenocarcinoma has progressed on at least one line of chemotherapy and was found to have an nrg1 gene fusion via somatic tumor testing. what options are there for subsequent treatment?': [{'zenocutuzumab'}],\n",
       " 'my patient with metastatic pancreatic cancer has a germline brca1 or brca2 mutation and has not had disease progression after at least 16 months of therapy. is there an option for maintenance therapy that can give my patient a break off chemotherapy?': [{'olaparib'}],\n",
       " 'my patient with metastatic or unresectable gastric or gastroesophageal junction adenocarcinoma has a pd-l1 cps (combined positive score) of at least 1 or greater and is her2+. what is the best first-line treatment option?': [{'cisplatin',\n",
       "   'fluorouracil',\n",
       "   'pembrolizumab',\n",
       "   'trastuzumab'},\n",
       "  {'capecitabine', 'oxaliplatin', 'pembrolizumab', 'trastuzumab'}],\n",
       " 'what is the preferred targeted therapy for metastatic urothelial carcinoma with fgfr3 mutation after progression on ev+pembro or platinum-based chemotherapy?': [{'erdafitinib  '}],\n",
       " 'what is a targeted therapy that should be considered for the management of patients with refractory lymphoid neoplasms with fgfr1 rearrangement?': [{'pemigatinib'}],\n",
       " 'what is a targeted therapy that can be used for the management of patients with relapsed or refractory follicular lymphoma with ezh2 mutation?': [{'tazemetostat'}],\n",
       " 'what is a targeted therapy that can be used for the treatment of relapsed/refractory systemic anaplastic large cell lymphoma that is alk positive?': [{'crizotinib'}],\n",
       " 'what is a potential treatment in patients with hormone receptor-positive, her2-negative, pik3ca-mutated, advanced or metastatic breast cancer who have experienced disease progression on or after an endocrine-based regimen?a': [{'alpelisib + fulvestrant'}],\n",
       " 'what is an acceptable treatment in patients with estrogen receptor-positive, her2-negative, esr1-mutated advanced or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy?': [{'elacestrant'}],\n",
       " 'what is an acceptable regimen in patients with metastatic her2-positive gastroesophageal junction adenocarcinoma, with cps >= 1?': [{'cisplatin',\n",
       "   'fluorouracil',\n",
       "   'pembrolizumab',\n",
       "   'trastuzumab'},\n",
       "  {'capecitabine', 'oxaliplatin', 'pembrolizumab', 'trastuzumab'}],\n",
       " 'are there any genomically guided therapies that are fda approved for prostate cancer?': [{'olaparib'},\n",
       "  {'enzalutamide', 'talazoparib'},\n",
       "  {'abiraterone acetate', 'niraparib', 'prednisone'},\n",
       "  {'abiraterone acetate', 'olaparib', 'prednisolone'},\n",
       "  {'abiraterone acetate', 'olaparib', 'prednisone'},\n",
       "  {'rucaparib'},\n",
       "  {'talazoparib'}],\n",
       " 'which drugs are currently approved for the treatment of desmoid tumors?': [{'nirogacestat'}],\n",
       " 'what are the current options for the first-line treatment of metastatic or advanced clear-cell kidney cancer?': [{'cabozantinib',\n",
       "   'nivolumab'},\n",
       "  {'ipilimumab', 'nivolumab'},\n",
       "  {'lenvatinib', 'pembrolizumab'},\n",
       "  {'axitinib', 'pembrolizumab'},\n",
       "  {'avelumab', 'axitinib'}]}"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "real_world_query_therapy_pair_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8c4a0ece",
   "metadata": {},
   "outputs": [],
   "source": [
    "save_object(real_world_query_therapy_pair_dict, f\"data/real_world_db/real_world_query_therapy_pair_dict.pkl\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
